Atrial fibrillation is the most common heart arrhythmia. Inappropriate contractile signals from the atria lead to rapid ventricular rate which, over time, increases the risk or exacerbation of heart failure. Subsequent inefficient flow from atria to ventricles increases the likelihood of clots to form, which can travel from the heart to brain, dramatically increasing stroke risk. As AF may be infrequent and asymptomatic, diagnosis is a large hurdle to treatment, which includes: acute restoration to normal rhythm through drug therapy or electric current, longer-term use of rate or rhythm control drugs, potential ablation of arrhythmogenic sites, and addressing stroke risk via administration of anticoagulant drugs or physical closure of the left atrial appendage (LAA, a common site for thrombus formation in AF). Advances in the last decade have focused on improving ablation technologies, anticoagulant efficacy and safety, and LAA closure techniques.
Medical Conference Coverage
CardioVascular Resource Group (CVrg) is a team of expert analysts who rigorously evaluate the latest new data releases, corporate reports, and news to distill important advances in complex therapeutic areas. Our comprehensive medical congress coverage and continuous market surveillance put these advances into the context of the overall atrial fibrillation and stroke prevention in AF competitive landscape to help guide strategic and tactical commercial development decisions for our clients.
